ACM
BNTC icon

ADAR1 Capital Management’s Benitec Biopharma BNTC Stock Holding History

ADAR1 Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186K Buy
+17,500
New +$203K 0.01% 263

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ADAR1 Capital Management's BNTC Position: Q1 2026 in Review

ADAR1 Capital Management opened a new position in Benitec Biopharma (BNTC) in Q1 2026: 17,500 shares worth $186K. The stake represents 0.01% of the portfolio and ranks #263 among its holdings.

88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • ADAR1 Capital Management held 17,500 shares of Benitec Biopharma worth $186K as of Q1 2026.
  • Benitec Biopharma was a new ADAR1 Capital Management position in Q1 2026.
  • Benitec Biopharma made up 0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #263 holding.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.